Anti-inflammatory foam-stabilizing composition and application thereof
By combining tea saponin with humate, an anti-inflammatory and foam-stabilizing composition was formed, which solved the problem of insufficient research on the combined use of tea saponin and humic acid, and achieved better anti-inflammatory, foaming and foam-stabilizing effects. In particular, the effect of sodium humate was significantly better than that of potassium humate.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-11
- Publication Date
- 2026-04-14
AI Technical Summary
There is a lack of research on the combined use of tea saponins and humic acid in the current technology, especially in terms of anti-inflammatory, foaming and foam stabilizing effects, and the effective treatment of camellia seed cake is an urgent problem to be solved.
By combining tea saponins with humates, an anti-inflammatory and foam-stabilizing composition is formed. Tea saponins reduce surface tension and promote foam formation, while humates enhance foam stability and have a synergistic anti-inflammatory effect, including the synergistic antioxidant effect and absorption promotion of tea saponins and humates.
It achieves better anti-inflammatory, foaming and foam stabilizing effects. The combination of tea saponin and humate significantly improves the stability and anti-inflammatory ability of foam, especially sodium humate, which is more effective than potassium humate.
Smart Images
Figure CN121845972A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of cosmetic technology, specifically to an anti-inflammatory and foam-stabilizing composition and its application. Background Technology
[0002] Tea saponins, also known as tea saponins, are a class of glycoside compounds. As a natural nonionic surfactant, tea saponins have good emulsifying, dispersing, foaming, and wetting functions, and also have anti-inflammatory, analgesic, and anti-permeability pharmacological effects.
[0003] The basic structure of humic acid macromolecules consists of aromatic and alicyclic rings, with functional groups such as carboxyl, hydroxyl, carbonyl, quinone, and methoxy groups attached to the rings. This structure determines their excellent hydrophilicity, complexing ability, ion exchange capacity, and adsorption capacity. Currently, besides its primary use as a soil conditioner and fertilizer in agriculture, humic acid also possesses anti-inflammatory properties. Humic acid is classified into "natural humic acid" and "synthetic humic acid."
[0004] From the perspective of classification, "natural humic acid" can be mainly divided into three categories: soil humic acid, aquatic humic acid, and coal humic acid (also known as mineral-derived humic acid). They are widely found in soils, lakes, rivers, oceans, and in peat, lignite, and weathered coal. Natural humic acid is formed from organic matter such as plant and animal remains under natural conditions through a series of complex biochemical processes. These processes include microbial decomposition and transformation, as well as natural chemical reactions; therefore, the formation of natural humic acid takes a very long time.
[0005] From the perspective of the types of "artificial humic acid," there are mainly three categories: bio-fermented humic acid, chemically synthesized humic acid, and oxidatively regenerated humic acid. Their raw material sources are very broad, including various fully exploitable agricultural by-products and renewable industrial waste such as crop straw, sawdust, sugar refining waste, furfural residue, brewing waste liquid, papermaking waste liquid, and animal manure. Artificial humic acid is produced using modern biotechnology, using crop straw, organic waste from industrial production, and kitchen waste as raw materials, through artificially controllable microbial fermentation and physicochemical processes. This method makes large-scale production and application of humic acid possible.
[0006] There is currently no research on the combined use of tea saponins and humic acid, or their use for anti-inflammatory and / or foaming and foam stabilizing purposes.
[0007] Camellia oil meal is the residue left after pressing camellia fruits for oil extraction, with or without shelling. How to effectively process camellia oil meal has become an urgent problem to be solved. Studies have shown that camellia oil meal is rich in high-value components such as tea saponins, polysaccharides, proteins, and polyphenols.
[0008] Therefore, it is essential to develop an anti-inflammatory and foam-stabilizing composition that can solve the above-mentioned technical problems and its application. Summary of the Invention
[0009] The purpose of this invention is to overcome the shortcomings of the prior art and provide an anti-inflammatory and foam-stabilizing composition and its application that has better effects in at least one of anti-inflammatory, foaming and foam-stabilizing properties.
[0010] This invention is achieved through the following technical solutions:
[0011] The first aspect of the present invention provides an anti-inflammatory and foam-stabilizing composition, comprising, by weight, 10-30 parts of tea saponin, 0.6-3 parts of humate, 20-30 parts of surfactant and 1-3 parts of polyol.
[0012] The synergistic anti-inflammatory principle of tea saponin and humate in this invention is as follows: ① Complementary target pathways, for example, tea saponin inhibits COX-2, while humate inhibits IL-6, and the two work together to achieve a more comprehensive effect; ② Enhanced antioxidant capacity, tea saponin scavenge free radicals, and humate provides more antioxidant sites; ③ Promotes mutual absorption or stability, with humate acting as a carrier to promote the penetration of tea saponin.
[0013] In this invention, tea saponin is responsible for reducing surface tension and promoting foam formation, while humate may assist tea saponin in foaming by increasing solution viscosity or interacting with tea saponin molecules to form a more stable foam structure. Furthermore, active groups (such as carboxyl and hydroxyl groups) in humate may form hydrogen bonds or other intermolecular forces with tea saponin molecules, enhancing foam stability.
[0014] As one embodiment of the present invention, the anti-inflammatory and foam-stabilizing composition comprises, by weight, 10-20 parts of tea saponin, 0.6-3 parts of humate, 20-30 parts of surfactant and 1-3 parts of polyol.
[0015] In one embodiment of the present invention, the surface activity includes at least one of sodium dodecyl sulfate, sodium lauryl sulfate, ammonium lauryl sulfate, cocamidopropyl betaine, and cocamidomethyl MEA.
[0016] In a preferred embodiment of the present invention, the surface active agent comprises sodium dodecyl sulfate, cocamidopropyl betaine, and cocamidomethyl MEA, wherein the mass ratio of the three is 1:0.1-1:0.1-1.
[0017] In one embodiment of the present invention, the polyol includes at least one of glycerol, propylene glycol, butylene glycol, panthenol, and sorbitol.
[0018] In one embodiment of the present invention, the humate includes at least one of sodium humate and potassium humate.
[0019] In one embodiment of the present invention, the tea saponin and the humate are commercial products with a purity of 90% to 99.5%.
[0020] In one embodiment of the present invention, the tea saponin is extracted from camellia seed cake.
[0021] In one embodiment of the present invention, the humate is preferably a plant-derived humate, and mineral-derived humates cannot be used.
[0022] In one embodiment of the present invention, the anti-inflammatory and foam-stabilizing composition further includes water.
[0023] Preferably, the amount of water used in the anti-inflammatory and foam-stabilizing composition is based on a total amount of 100 parts of the anti-inflammatory and foam-stabilizing composition, that is, water is added until the amount of the anti-inflammatory and foam-stabilizing composition is 100 parts.
[0024] A second aspect of the present invention provides the application of the above-described anti-inflammatory and foam-stabilizing composition in the preparation of a product having at least one of anti-inflammatory, foaming, and foam-stabilizing effects.
[0025] As one embodiment of the present invention, when the anti-inflammatory and foam-stabilizing composition includes water (i.e., in aqueous solution form), the mass percentage of the anti-inflammatory and foam-stabilizing composition in the product is 0.05-20%.
[0026] In one embodiment of the present invention, the product is a cosmetic.
[0027] The beneficial effects of this invention are: In this invention, tea saponin and humate are used in combination, which have a significant synergistic effect in anti-inflammatory, foaming and foam stabilizing properties. In particular, the effect of sodium humate is significantly better than that of potassium humate. Attached Figure Description
[0028] Figure 1 This is a diagram showing the foam height of the product after foaming in Example 1.
[0029] Figure 2 This is a diagram showing the foam height of the product after foaming in Example 2.
[0030] Figure 3 This is a diagram showing the foam height of the product after foaming in Example 3.
[0031] Figure 4 This is a diagram showing the foam height of the product after foaming in Example 4.
[0032] Figure 5 This is a diagram showing the foam height of product 3 after foaming.
[0033] Figure 6 This is a diagram showing the foam height of product 4 after foaming.
[0034] Figure 7 This is a diagram showing the foam height of product 6 after foaming.
[0035] Figure 8 This is the stability test result of the product in Example 1.
[0036] Figure 9 This is the stability test result of the product in Example 2.
[0037] Figure 10 This is the stability test result of the product in Example 3.
[0038] Figure 11 This is the stability test result of the product in Example 4. Detailed Implementation
[0039] The present invention will be further described below with reference to specific embodiments, and the advantages and features of the present invention will become clearer as a result. However, these embodiments are merely exemplary and do not constitute any limitation on the scope of the present invention. Those skilled in the art should understand that modifications or substitutions can be made to the details and form of the technical solutions of the present invention without departing from the spirit and scope of the present invention, but all such modifications and substitutions fall within the protection scope of the present invention.
[0040] The tea saponins used in the following examples were purchased from Shanghai Maclean Biochemical Technology Co., Ltd., catalog number T723191, extracted from camellia seed cake, with a purity of 95%; sodium humate was purchased from Shanghai Maclean Biochemical Technology Co., Ltd., catalog number H810850-500g, and is of plant origin; potassium humate was purchased from Shanghai Maclean Biochemical Technology Co., Ltd., catalog number P885827-100, and is of plant origin.
[0041] Example 1 An anti-inflammatory and foam-stabilizing composition, by weight, comprises the following: 10 parts tea saponin, 3 parts sodium humate, 15 parts sodium lauryl ether sulfate, 3 parts cocamidopropyl betaine, 2 parts cocamidomethyl MEA, and 3 parts glycerin, with water added to a total composition of 100 parts.
[0042] The preparation process of the anti-inflammatory and foam-stabilizing composition is as follows: the raw materials are directly mixed evenly to obtain the final product.
[0043] Example 2 Compared with Example 1, the only difference is that sodium humate is replaced with potassium humate, and all other conditions are the same, as follows: An anti-inflammatory and foam-stabilizing composition, by weight, comprises the following: 10 parts tea saponin, 3 parts potassium humate, 15 parts sodium lauryl ether sulfate, 3 parts cocamidopropyl betaine, 2 parts cocamidomethyl MEA, and 3 parts glycerin, with water added to a total composition of 100 parts.
[0044] The preparation process of the anti-inflammatory and foam-stabilizing composition is the same as in Example 1.
[0045] Example 3 An anti-inflammatory and foam-stabilizing composition, by weight, comprises the following: 15 parts tea saponin, 0.6 parts sodium humate, 15 parts sodium lauryl sulfate, 7 parts cocamidopropyl betaine, 8 parts cocamidomethyl MEA, and 1 part glycerin, with water added to bring the total composition to 100 parts.
[0046] The preparation process of the anti-inflammatory and foam-stabilizing composition is the same as in Example 1.
[0047] Example 4 An anti-inflammatory and foam-stabilizing composition, by weight, comprises the following: 30 parts tea saponin, 0.6 parts sodium humate, 15 parts sodium lauryl sulfate, 7 parts cocamidopropyl betaine, 8 parts cocamidomethyl MEA, and 1 part glycerin, with water added to a total composition of 100 parts.
[0048] The preparation process of the anti-inflammatory and foam-stabilizing composition is the same as in Example 1.
[0049] Comparative Example 1 Compared with Example 1, the only difference is that it does not contain sodium humate, and the amount of tea saponin is adjusted to 13 parts.
[0050] Comparative Example 2 Compared to Example 1, the only difference is that it does not contain tea saponin, and the amount of sodium humate is adjusted to 13 parts.
[0051] Comparative Example 3 Compared to Example 1, the only difference is that it does not contain tea saponins and humates.
[0052] Comparative Example 4 Compared to Example 1, the only difference is that sodium humate is not included, and the amount of tea saponin remains at 10 parts.
[0053] Comparative Example 5 Compared with Example 1, the only difference is the ratio of tea saponin and sodium humate used. The total amount of both is kept at 13 parts, and the ratio is adjusted to 1:1.
[0054] Comparative Example 6 Compared with Example 1, the only difference is the ratio of tea saponin and sodium humate used. The total amount of both is kept at 13 parts, and the ratio is adjusted to 55:1.
[0055] Test Example 1 The test was conducted according to T / SHRH 034-2021 "Test Method for Soothing Efficacy of Cosmetics - In Vitro Determination of TNF-α Inflammatory Factor Content in Lipopolysaccharide-Induced Macrophages RAW264.7". The specific steps are as follows: RAW 264.7 cells were removed from the liquid nitrogen tank and rapidly thawed by shaking in a 37°C water bath. After thawing, the frozen cells were quickly transferred to culture dishes containing DMEM medium and placed in a 37°C, 5% CO2 incubator for culture. A negative control group (containing only cells and culture medium), a lipopolysaccharide LPS model group (containing cells, culture medium, and LPS, with a final LPS concentration of 1 μg / mL to simulate inflammatory response), and an experimental group (containing cells, culture medium, 1 μg / mL LPS, and different concentrations of anti-inflammatory and vesicle-stabilizing compositions) were set up. RAW264.7 cells were seeded into 96-well plates. After 24 h, culture medium was added to the negative control group, the lipopolysaccharide LPS model group, and the experimental group, respectively. The cell supernatant was collected and centrifuged. The supernatant was collected, and the IL-6 content in the cell culture supernatant was measured using an ELISA kit to determine the effect of the experimental sample on the IL-6 content of macrophages. The relative IL-6 content = IL-6 content of the sample / IL-6 content of the negative control group × 100%.
[0056] In Example 1, the levels of IL-6 inflammatory cytokines in cells were approximately 46.12% and 61.78% of those in the negative control group, respectively, demonstrating a significant inhibitory effect on IL-6 inflammatory cytokines levels (P<0.01). The remaining examples and comparative examples used the same testing method to test the relative IL-6 inflammatory cytokines levels at 0.05% and 0.1% mass concentrations of the anti-inflammatory and vesicle-stabilizing composition (referring to the mass percentage concentration of the anti-inflammatory and vesicle-stabilizing composition in the culture medium). The results are shown in Table 1.
[0057] Table 1. IL-6 inflammatory factor level test
[0058] Test Example 2 2.5g of each anti-inflammatory and foam-stabilizing composition from the examples and comparative examples were added to 1000mL of water as the test solution. The foam height after foaming was tested according to the national standard GB / T 13173-2021 "Test Methods for Surfactants and Detergents". 200mL of the test solution was poured from a height of 90cm onto the surface of 50mL of the same test solution at the bottom of the graduated cylinder. The initial surface foam height was measured as the foaming effect of the sample. The foam height was measured again after 15 minutes as the foam stabilizing effect of the sample. Each sample was tested twice. The surface foam height results for each composition are shown in Table 2. The effects of Examples 1-4 are as follows: Figures 1-4As shown, the effects of comparative examples 3, 4, and 6 are respectively as follows: Figures 5-7 As shown.
[0059] Table 2 Foaming and foam stabilization results
[0060] Test Example 3 Stability Test The stability of the anti-inflammatory and foam-stabilizing composition is mainly analyzed by utilizing the movement of particles under gravity or centrifugal force and optical near-infrared detection technology.
[0061] The test method is as follows: (1) Put the sample into a special sample tube; (2) Shake the sample gently to avoid generating air bubbles; (3) Set the test parameters on the operation panel or the supporting software: contour line 1000, time interval: 45s, rotation speed: 2500 rpm; after setting the temperature, light factor: 1.00, temperature: 45℃; (4) After the temperature rises to the set temperature of 45℃, put the sample tube into the instrument rotor and start the instrument. The stability of the sample is evaluated by the particles settling for 12 hours under the action of gravity. In a stable sample, the particles move slowly or hardly move; while in an unstable sample, the particles settle or float quickly, forming a stratification phenomenon. The stability of the sample can be evaluated by measuring the particle movement speed. At the same time, the sample stability is evaluated by irradiating the entire sample tube with near-infrared light or blue light in parallel and detecting the change in the transmittance of the sample through a high-precision optical system.
[0062] The test results of Examples 1-4 are as follows: Figures 8-11 As shown.
[0063] The above detailed description is a specific description of one of the feasible embodiments of the present invention. This embodiment is not intended to limit the patent scope of the present invention. All equivalent implementations or modifications that do not depart from the present invention should be included within the scope of the technical solution of the present invention.
Claims
1. An anti-inflammatory and foam-stabilizing composition, characterized in that, Based on parts by weight, it includes 10-30 parts tea saponin, 0.6-3 parts humate, 20-30 parts surfactant, and 1-3 parts polyol.
2. The anti-inflammatory and foam-stabilizing composition according to claim 1, characterized in that, Based on parts by weight, it includes 10-20 parts tea saponin, 0.6-3 parts humate, 20-30 parts surfactant, and 1-3 parts polyol.
3. The anti-inflammatory and foam-stabilizing composition according to any one of claims 1-2, characterized in that, The surface actives include at least one of sodium dodecyl sulfate, sodium lauryl sulfate, ammonium lauryl sulfate, cocamidopropyl betaine, and cocamidomethyl MEA.
4. The anti-inflammatory and foam-stabilizing composition according to claim 3, characterized in that, The surface actives include sodium dodecyl sulfate, cocamidopropyl betaine, and cocamidomethyl MEA in a mass ratio of 1:0.1-1:0.1-1.
5. The anti-inflammatory and foam-stabilizing composition according to any one of claims 1-2, characterized in that, The polyols include at least one of glycerol, propylene glycol, butylene glycol, panthenol, and sorbitol.
6. The anti-inflammatory and foam-stabilizing composition according to any one of claims 1-2, characterized in that, The humate includes at least one of sodium humate and potassium humate.
7. The anti-inflammatory and foam-stabilizing composition according to any one of claims 1-2, characterized in that, The tea saponin is obtained by extracting from camellia seed cake; and / or the humate is a plant-derived humate.
8. The anti-inflammatory and foam-stabilizing composition according to any one of claims 1-2, characterized in that, The anti-inflammatory and foam-stabilizing composition also includes water.
9. The anti-inflammatory and foam-stabilizing composition according to claim 8, characterized in that, The amount of water used is based on a total of 100 parts of the anti-inflammatory and foam-stabilizing composition.
10. The use of the anti-inflammatory and foam-stabilizing composition according to any one of claims 1-9 in the preparation of a product, said product having at least one of anti-inflammatory, foaming and foam-stabilizing effects.